<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
        <title>Severe Combined Immunodeficiencies</title>
        <meta name="viewport" content="width=device-width">

        <!-- syntax highlighting CSS -->
        <link rel="stylesheet" href="/css/syntax.css">

        <!-- Custom CSS -->
        <link rel="stylesheet" href="/css/main.css">

		<!-- Set refresh timer for local development 
		<meta http-equiv="refresh" content="10" />-->
		
    </head>
    <body>

        <div class="container">
          <div class="site">

			<h1>Severe Combined Immunodeficiencies</h1>
			<p class="meta">28 Jan 2014</p>

			<div class="post">
			<h3 id="objectives">Objectives</h3>
<ul>
  <li>Recognize the typical clinical presentation of SCID</li>
  <li>Understand the different categories and genetic causes of SCID</li>
  <li>Understand pathogenesis and adenosine deaminase deficient SCID</li>
  <li>Develop basic understanding of laboratory evaluation and treatment options for SCID.</li>
</ul>

<p><span><br /></span> </p>

<h3 id="scid-case-presentation">SCID Case presentation</h3>
<ul>
  <li>HPI: 15 m/o F presenting w/ 4th episode of PNA.</li>
  <li>Physical: FTT, afebrile, multiple findings.</li>
  <li>CBC at admission: WBC 3.4, 3% lymphs  (ALC 72)</li>
  <li>CXR: normal at 6 months, now with bilateral lower lobe infiltrates. Absent thymic shadow.</li>
  <li>Chest CT: brochiectasis and bilateral patchy infiltrates.</li>
  <li>Blood: Low IgG, very low CD3+, CD4+, CD8+. Plasma ADA level = 0, dAXP = 0.347.</li>
  <li>Assessment: Consistent with ADA deficient SCID.</li>
  <li>Treatment: IVIG infusions and ADA enzyme replacement therapy (Adagen). Patient did develop cellulitis, sepsis, and EBV infection before immune modulation. 3 months after Adagen, dAXP was undetectable and normal lymphocyte count had returned. 12 months of adagen, IVIG was able to be discontinued.</li>
</ul>

<p><span><br /></span></p>

<h3 id="scid-overview">SCID Overview</h3>
<ul>
  <li>Disorder of T cell number and function with variable B cell and NK cell defects.</li>
  <li>Present within first several months of life with chronic diarrhea, FTT, and emaciation.</li>
  <li>Recurrent infections typically involve fungi, viruses, and opportunistic infections. </li>
  <li>Fatal within 2 years without immune reconstitution.</li>
</ul>

<p><span><br /></span></p>

<h3 id="scid-classification">SCID Classification</h3>
<ul>
  <li>T lymphocytopenia is consistent in all classical SCID</li>
  <li>Impact on B cells and NK cells is variable, depending on the genetic defect.</li>
  <li>“Leaky” SCID might have some abnormal circulating T cells.</li>
  <li>Remember to compare cell levels with age-specific groups! Lymphopenia in infancy is 3000 cells/ml, T-cell lymphopenia is 1800 cells/ml</li>
  <li><strong>T-B-NK- SCID</strong>: pan-lymphocyte development defect, very early defect. Cell-toxicity metabolic defect could also do this. Reticular dysgenesis, ADA deficiency.</li>
  <li><strong>T-B-NK+ SCID</strong>: failure of T-cell and B-cell antigen receptor development. Protein deficiencies “stop the rearrangements from happening.” Recombinant genes are the cause here. (RAG, Artemis, Ligase IV, PNP).</li>
  <li><strong>T-B+NK- SCID</strong>: IL-2 gamma chain deficiency, Jak3 deficiency.</li>
  <li><strong>T-B+NK+ SCID</strong>: Defect in the CD3 receptor. IL-7R(alpha), CD3(gamma, epsilon, delta) deficiencies</li>
  <li>Mutations in only 10 genes account for more than 95% of SCID</li>
</ul>

<p><span><br /></span></p>

<h3 id="adenosine-deaminase-deficiency">Adenosine Deaminase Deficiency</h3>
<ul>
  <li>Normal lymphocytes: dATP breaks down to deoxyadenosine. ADA breaks deoxyadenosine to deoxyinosine, which then gets broken down to uric acid and excreted. </li>
  <li>ADA deficiency leads to build up of dATP, causing cell death.</li>
  <li>15% of SCID have ADA, 85% of those are lymphopenic at birth.</li>
  <li>Highest ADA activity is in lymphoid cells, especially immature thymocytes, thus most significantly affected by toxicity when deficient.</li>
  <li>Other organ systems are involved: skeletal dysplasia, liver dysfunction, neurologicla symptoms</li>
  <li>SCID is an immunological emergency: infants are healthy are birth but die due to severe infections in infancy and is uniformly fatal if immune reconstitution is not performed.</li>
  <li>Survival for 3.5 years after bone marrow transplant is 95%.</li>
  <li>Early identification is essential because rotavirus vaccine is a live-attenuated vaccine and will cause pathology in SCID.</li>
  <li>Lab evaluation: get an absolute lymphocyte count, quantify T cells and susets, evaluate for naive T cells, genetic testing for specific mutations. Of note, newborn screening for T-cell defects is now being performed in 26 states.</li>
  <li>TREC positive: indicates that T cells have undergone V-(D)-J rearrangement. Sign of a healthy T-cell in the peripheral blood.</li>
</ul>

<p><span><br /></span></p>

<h3 id="treatment-options-in-scid">Treatment Options in SCID</h3>
<ul>
  <li><em>Hematopoietic stem cell transplantation</em>: from a matched related family donor, or a haplo-indentical family donor, matched unrelated donor. </li>
  <li><em>Gene therapy</em>: delayed due to clonal expansion and malignancy in X-SCID and CGD.</li>
  <li><em>Enzyme replacement</em>: Adagen can replace adenosine deaminase in ADA-SCID, but 20% don’t respond and 40% still need IVIG.</li>
</ul>

			</div>
			<br>
			<hr>
            <div class="footer">
			<h6><p><a href="/">&#60; Back</a></p></h6>
			</div>
           	<div class="contact">
                <p>
					<a href="http://bquarant.github.io/">bquarant.github.io</a> | 2014 
               </p>
              </div>
          </div>
        </div>

<!-- Track traffic on gaug.es-->
		<script type="text/javascript">
		  var _gauges = _gauges || [];
		  (function() {
		    var t   = document.createElement('script');
		    t.type  = 'text/javascript';
		    t.async = true;
		    t.id    = 'gauges-tracker';
		    t.setAttribute('data-site-id', '51f19a5df5a1f51079000024');
		    t.src = '//secure.gaug.es/track.js';
		    var s = document.getElementsByTagName('script')[0];
		    s.parentNode.insertBefore(t, s);
		  })();
		</script>
    </body>
</html>